Dabigatan 110 mg twice daily + P2Y12 inhibitor (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily)

Dabigatan 150 mg twice daily + P2Y12 inhibitor (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily)

Traditional triple therapy: ASA + clopidogrel + warfarin

Time to first major or clinically relevant non-major bleeding event

Dual therapy with dabigatran 110 mg twice daily: 15.4%
Triple therapy group: 26.9% (p<0.001)

Dual therapy with dabigatran 150 mg twice daily: 20.0%
Corresponding triple therapy group: 25.7% (p=0.002)

• Prevalence of AF: 100%
• Clopidogrel used as the P2Y12 inhibitor in 88% of patients (ticagrelor in 12% of patients); Not powered to detect differences in efficacy; Use of PPI: not provide